Physician profile
Aneeqa Dar
NPI 1558744920
$1,584.85
in general payments reported to CMS, 2019-2025
19 companies · $283 in 2025
The $283 reported for 2025 was more than what 83% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.93 · 2020: $102 · 2021: $207 · 2022: $240 · 2023: $424 · 2024: $310 · 2025: $283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,018.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,017.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $337.30 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $188.75 | 2020-2023 | Farxiga |
| Alexion Pharmaceuticals, INC. | $149.32 | 2021-2025 | Ultomiris, Soliris |
| Integra Lifesciences Corporation | $141.02 | 2023 | Tenoglide |
| Novartis Pharmaceuticals Corporation | $115.44 | 2019-2024 | |
| Mallinckrodt Hospital Products INC. | $94.31 | 2024-2025 | Terlivaz |
| Ferring Pharmaceuticals INC. | $90.27 | 2023-2024 | Rebyota |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.36 | 2021-2025 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $71.56 | 2021-2024 | Camzyos |
| Janssen Pharmaceuticals, INC | $61.56 | 2020-2021 | |
| Csl Behring | $44.07 | 2020-2022 | |
| Ceribell, INC. | $41.34 | 2025 | Pocket Eeg Device |
| Alcresta Therapeutics, INC. | $31.98 | 2024 | Relizorb |
| Abbvie INC. | $26.34 | 2024 | |
| Atricure, INC. | $25.82 | 2025 | Atriclip Laa Exclusion System |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $23.77 | 2021 | |
| Eisai INC. | $22.90 | 2024 | |
| Genzyme Corporation | $22.59 | 2022 | |
| Gilead Sciences, INC. | $16.15 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aneeqa Dar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.